Liver Cancer

>

Latest News

Investigators of the HEPATORCH trial will present additional data on toripalimab plus bevacizumab in this population at a future academic conference.
Toripalimab Combo May Improve Survival Vs Sorafenib in Advanced HCC

June 13th 2024

Investigators of the HEPATORCH trial will present additional data on toripalimab plus bevacizumab in this population at a future academic conference.

The 5-year follow-up results from CheckMate 040 showed consistent responses with nivolumab/ipilimumab in advanced hepatocellular carcinoma.
Nivolumab/Ipilimumab Yields Sustained Responses in Advanced HCC

May 30th 2024

The agency issues a complete response letter for the combination due to deficiencies associated with a manufacturing site inspection.
FDA Sends CRL for Camrelizumab/Rivoceranib in Unresectable Liver Cancer

May 20th 2024

Data from 10 new randomized clinical trials support updated recommendations for various systemic therapy regimens in hepatocellular carcinoma.
ASCO Guideline Issues Updated Systemic Therapy Recommendations in HCC

April 26th 2024

The safety of nivolumab plus ipilimumab among those with hepatocellular carcinoma in the CheckMate-9DW trial appears to be comparable with prior reports.
Nivolumab/Ipilimumab Significantly Improves OS in Advanced Liver Cancer

March 21st 2024

Latest CME Events & Activities

The 14th Asia-Pacific Primary Liver Cancer Expert Meeting

July 18 - 20, 2024

Register Now!

Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®

View More

2024 International Symposium of Gastrointestinal Oncology (ISGIO)

October 11-12, 2024

Register Now!

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer

View More

The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape

View More

Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®

View More

BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC

View More

More News

Sintilimab Plus Bevacizumab Biosimilar IBI305 Demonstrates OS and PFS Benefit Over Sorafenib in HCC

Sintilimab Plus Bevacizumab Biosimilar IBI305 Demonstrates OS and PFS Benefit Over Sorafenib in HCC

Ariana Pelosci
July 23rd 2021

Patients with unresectable hepatitis B virus–positive hepatocellular carcinoma have achieved significantly better overall survival and progression-free survival following treatment with sintilimab plus IBI305 vs sorafenib.

<123